Network dynamics in the tumor microenvironment

Seminars in Cancer Biology

Volumn 30, Issue , 2015, Pages 52-59

  Bolouri, Hamid ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Big Data; Bioinformatics; Computational biology; Modeling; Network biology; Systems biology; Tumor microenvironment

Indexed keywords

BIOINFORMATICS; CANCER GROWTH; CANCER RESISTANCE; CANCER THERAPY; CELL INTERACTION; COMPUTER MODEL; DORMANCY; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; MATHEMATICAL MODEL; MOLECULAR MODEL; NETWORK DYNAMICS; REVIEW; SYSTEMS BIOLOGY; TUMOR MICROENVIRONMENT; CHEMICAL STRUCTURE; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

HUMANS; MODELS, MOLECULAR; NEOPLASMS; SYSTEMS BIOLOGY; TUMOR MICROENVIRONMENT;

EID: 84919634618     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2014.02.007     Document Type: Review

References (76)

1. Stratton M.R. Exploring the genomes of cancer cells: progress and promise. Science 2011, 331:1553-1558.
2. Cukierman E., Bassi D.E. The mesenchymal tumor microenvironment: a drug-resistant niche. Cell Adh Migr 2012, 6:285-296.
3. Meads M.B., Gatenby R.A., Dalton W.S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009, 9:665-674.
4. Lorusso G., Ruegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008, 130:1091-1103.
5. Polyak K., Haviv I., Campbell I.G. Co-evolution of tumor cells and their microenvironment. Trends Genet 2009, 25:30-38.
6. Bissell M.J., Hines W.C. Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat Med 2011, 17:320-329.
7. Soto A.M., Sonnenschein C. The tissue organization field theory of cancer: a testable replacement for the somatic mutation theory. Bioessays 2011, 33:332-340.
8. Bolouri H. Computational modeling of gene regulatory networks: a primer 2008, Imperial College Press/Distributed by World Scientific Pub., London/Hackensack, NJ.
9. Swartz M.A., Iida N., Roberts E.W., Sangaletti S., Wong M.H., Yull F.E., et al. Tumor microenvironment complexity: emerging roles in cancer therapy. Cancer Res 2012, 72:2473-2480.
10. Wallace D.C. Mitochondria and cancer. Nat Rev Cancer 2012, 12:685-698.
11. Furuta S., Jeng Y.M., Zhou L., Huang L., Kuhn I., Bissell M.J., et al. IL-25 causes apoptosis of IL-25R-expressing breast cancer cells without toxicity to nonmalignant cells. Sci Transl Med 2011, 3:78ra31.
12. Tripathi M., Billet S., Bhowmick N.A. Understanding the role of stromal fibroblasts in cancer progression. Cell Adh Migr 2012, 6:231-235.
13. Watnick R.S. The role of the tumor microenvironment in regulating angiogenesis. Cold Spring Harb Perspect Med 2012, 2:a006676.
14. Gajewski T.F., Schreiber H., Fu Y.X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013, 14:1014-1022.
15. Onodera Y., Nam J.M., Bissell M.J. Increased sugar uptake promotes oncogenesis via EPAC/RAP1 and O-GlcNAc pathways. J Clin Invest 2014, 124:367-384.
16. Becker-Weimann S., Xiong G., Furuta S., Han J., Kuhn I., Akavia U.D., et al. NFkB disrupts tissue polarity in 3D by preventing integration of microenvironmental signals. Oncotarget 2013, 4:2010-2020.
17. Kreeger P.K., Lauffenburger D.A. Cancer systems biology: a network modeling perspective. Carcinogenesis 2010, 31:2-8.
18. Katira P., Bonnecaze R.T., Zaman M.H. Modeling the mechanics of cancer: effect of changes in cellular and extra-cellular mechanical properties. Front Oncol 2013, 3:145.
19. Harjanto D., Zaman M.H. Modeling extracellular matrix reorganization in 3D environments. PLoS ONE 2013, 8:e52509.
20. Bissell M.J., Hall H.G., Parry G. How does the extracellular matrix direct gene expression. J Theor Biol 1982, 99:31-68.
21. Logue J.S., Morrison D.K. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. Genes Dev 2012, 26:641-650.
22. Dreesen O., Brivanlou A.H. Signaling pathways in cancer and embryonic stem cells. Stem Cell Rev 2007, 3:7-17.
23. Millard B.L., Niepel M., Menden M.P., Muhlich J.L., Sorger P.K. Adaptive informatics for multifactorial and high-content biological data. Nat Methods 2011, 8:487-493.
24. Saez-Rodriguez J., Alexopoulos L.G., Zhang M., Morris M.K., Lauffenburger D.A., Sorger P.K. Comparing signaling networks between normal and transformed hepatocytes using discrete logical models. Cancer Res 2011, 71:5400-5411.
25. Niepel M., Hafner M., Pace E.A., Chung M., Chai D.H., Zhou L., et al. Profiles of basal and stimulated receptor signaling networks predict drug response in breast cancer lines. Sci Signal 2013, 6:ra84.
26. Stasyk T., Huber L.A. Mapping in vivo signal transduction defects by phosphoproteomics. Trends Mol Med 2012, 18:43-51.
27. Kreeger P.K., Mandhana R., Alford S.K., Haigis K.M., Lauffenburger D.A. RAS mutations affect tumor necrosis factor-induced apoptosis in colon carcinoma cells via ERK-modulatory negative and positive feedback circuits along with non-ERK pathway effects. Cancer Res 2009, 69:8191-8199.
28. Furey T.S. ChIP-seq and beyond: new and improved methodologies to detect and characterize protein-DNA interactions. Nat Rev Genet 2012, 13:840-852.
29. Beronja S., Fuchs E. RNAi-mediated gene function analysis in skin. Methods Mol Biol 2013, 961:351-361.
30. Beronja S., Livshits G., Williams S., Fuchs E. Rapid functional dissection of genetic networks via tissue-specific transduction and RNAi in mouse embryos. Nat Med 2010, 16:821-827.
31. Ghajar C.M., Bissell M.J. Tumor engineering: the other face of tissue engineering. Tissue Eng Part A 2010, 16:2153-2156.
32. Mori H., Borowsky A.D., Bhat R., Ghajar C.M., Seiki M., Bissell M.J. Laser scanning-based tissue autofluorescence/fluorescence imaging (LS-TAFI), a new technique for analysis of microanatomy in whole-mount tissues. Am J Pathol 2012, 180:2249-2256.
33. Carrion B., Huang C.P., Ghajar C.M., Kachgal S., Kniazeva E., Jeon N.L., et al. Recreating the perivascular niche ex vivo using a microfluidic approach. Biotechnol Bioeng 2010, 107:1020-1028.
34. Armitage P., Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. Br J Cancer 1954, 8:1-12.
35. Gatenby R.A., Gillies R.J. A microenvironmental model of carcinogenesis. Nat Rev Cancer 2008, 8:56-61.
36. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
37. Orlando P.A., Gatenby R.A., Brown J.S. Tumor evolution in space: the effects of competition colonization tradeoffs on tumor invasion dynamics. Front Oncol 2013, 3:45.
38. Anderson A.R., Weaver A.M., Cummings P.T., Quaranta V. Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment. Cell 2006, 127:905-915.
39. Quaranta V., Rejniak K.A., Gerlee P., Anderson A.R. Invasion emerges from cancer cell adaptation to competitive microenvironments: quantitative predictions from multiscale mathematical models. Semin Cancer Biol 2008, 18:338-348.
40. Martin N.K., Gaffney E.A., Gatenby R.A., Maini P.K. Tumour-stromal interactions in acid-mediated invasion: a mathematical model. J Theor Biol 2010, 267:461-470.
41. Lee H.O., Silva A.S., Concilio S., Li Y.S., Slifker M., Gatenby R.A., et al. Evolution of tumor invasiveness: the adaptive tumor microenvironment landscape model. Cancer Res 2011, 71:6327-6337.
42. Gao X., McDonald J.T., Hlatky L., Enderling H. Acute and fractionated irradiation differentially modulate glioma stem cell division kinetics. Cancer Res 2013, 73:1481-1490.
43. Mukhopadhyay R., Costes S.V., Bazarov A.V., Hines W.C., Barcellos-Hoff M.H., Yaswen P. Promotion of variant human mammary epithelial cell outgrowth by ionizing radiation: an agent-based model supported by in vitro studies. Breast Cancer Res 2010, 12:R11.
44. Szabo A., Merks R.M. Cellular potts modeling of tumor growth, tumor invasion, and tumor evolution. Front Oncol 2013, 3:87.
45. Scianna M., Preziosi L., Wolf K. A Cellular Potts Model simulating cell migration on and in matrix environments. Math Biosci Eng 2013, 10:235-261.
46. Perfahl H., Byrne H.M., Chen T., Estrella V., Alarcon T., Lapin A., et al. Multiscale modelling of vascular tumour growth in 3D: the roles of domain size and boundary conditions. PLoS ONE 2011, 6:e14790.
47. Finley S.D., Popel A.S. Predicting the effects of anti-angiogenic agents targeting specific VEGF isoforms. AAPS J 2012, 14:500-509.
48. Finley S.D., Popel A.S. Effect of tumor microenvironment on tumor VEGF during anti-VEGF treatment: systems biology predictions. J Natl Cancer Inst 2013, 105:802-811.
49. Kim Y., Othmer H.G. A hybrid model of tumor-stromal interactions in breast cancer. Bull Math Biol 2013, 75:1304-1350.
50. Bower J.M., Bolouri H. Computational modeling of genetic and biochemical networks 2001, MIT Press, Cambridge, MA.
51. Gurdon J.B. A community effect in animal development. Nature 1988, 336:772-774.
52. Bolouri H., Davidson E.H. Modeling transcriptional regulatory networks. Bioessays 2002, 24:1118-1129.
53. Bolouri H., Davidson E.H. The gene regulatory network basis of the community effect, and analysis of a sea urchin embryo example. Dev Biol 2010, 340:170-178.
54. Fan Q.W., Cheng C.K., Gustafson W.C., Charron E., Zipper P., Wong R.A., et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell 2013, 24:438-449.
55. Garnett J., Chumbalkar V., Vaillant B., Gururaj A.E., Hill K.S., Latha K., et al. Regulation of HGF expression by DeltaEGFR-mediated c-Met activation in glioblastoma cells. Neoplasia 2013, 15:73-84.
56. Lokker N.A., Sullivan C.M., Hollenbach S.J., Israel M.A., Giese N.A. Platelet-derived growth factor (PDGF) autocrine signaling regulates survival and mitogenic pathways in glioblastoma cells: evidence that the novel PDGF-C and PDGF-D ligands may play a role in the development of brain tumors. Cancer Res 2002, 62:3729-3735.
57. Nazarenko I., Hede S.M., He X., Hedren A., Thompson J., Lindstrom M.S., et al. PDGF and PDGF receptors in glioma. Ups J Med Sci 2012, 117:99-112.
58. Uhrbom L., Hesselager G., Ostman A., Nister M., Westermark B. Dependence of autocrine growth factor stimulation in platelet-derived growth factor-B-induced mouse brain tumor cells. Int J Cancer 2000, 85:398-406.
59. Dai C., Celestino J.C., Okada Y., Louis D.N., Fuller G.N., Holland E.C. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001, 15:1913-1925.
60. Fomchenko E.I., Dougherty J.D., Helmy K.Y., Katz A.M., Pietras A., Brennan C., et al. Recruited cells can become transformed and overtake PDGF-induced murine gliomas in vivo during tumor progression. PLoS ONE 2011, 6:e20605.
61. Massey S.C., Assanah M.C., Lopez K.A., Canoll P., Swanson K.R. Glial progenitor cell recruitment drives aggressive glioma growth: mathematical and experimental modelling. J R Soc Interface 2012, 9:1757-1766.
62. Todaro G.J., de Larco J.E. Growth factors produced by sarcoma virus-transformed cells. Cancer Res 1978, 38:4147-4154.
63. Sporn M.B., Roberts A.B. Autocrine growth factors and cancer. Nature 1985, 313:745-747.
64. Castellano G., Reid J.F., Alberti P., Carcangiu M.L., Tomassetti A., Canevari S. New potential ligand-receptor signaling loops in ovarian cancer identified in multiple gene expression studies. Cancer Res 2006, 66:10709-10719.
65. Ray A., Meng E., Reed E., Shevde L.A., Rocconi R.P. Hedgehog signaling pathway regulates the growth of ovarian cancer spheroid forming cells. Int J Oncol 2011, 39:797-804.
66. Schmid S., Bieber M., Zhang F., Zhang M., He B., Jablons D., et al. Wnt and hedgehog gene pathway expression in serous ovarian cancer. Int J Gynecol Cancer 2011, 21:975-980.
67. Sher I., Adham S.A., Petrik J., Coomber B.L. Autocrine VEGF-A/KDR loop protects epithelial ovarian carcinoma cells from anoikis. Int J Cancer 2009, 124:553-561.
68. Kulbe H., Chakravarty P., Leinster D.A., Charles K.A., Kwong J., Thompson R.G., et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 2012, 72:66-75.
69. Bellovin D.I., Das B., Felsher D.W. Tumor dormancy, oncogene addiction, cellular senescence, and self-renewal programs. Adv Exp Med Biol 2013, 734:91-107.
70. Polzer B., Klein C.A. Metastasis awakening: the challenges of targeting minimal residual cancer. Nat Med 2013, 19:274-275.
71. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007, 7:834-846.
72. Aguirre-Ghiso J.A., Bragado P., Sosa M.S. Metastasis awakening: targeting dormant cancer. Nat Med 2013, 19:276-277.
73. Terai H., Soejima K.N., Yasuda H., Nakayama S., Hamamoto J., Arai D., et al. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC cells. Mol Cancer Res 2013, 11(7):759-767.
74. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol 2012, 196:395-406.
75. Baxter L.L., Moreland R.T., Nguyen A.D., Wolfsberg T.G., Pavan W.J. A curated online resource for SOX10 and pigment cell molecular genetic pathways. Database (Oxford) 2010, 2010. baq025.
76. Bolouri H. Modeling genomic regulatory networks with big data. Trends Genet 2014, [Accepted for publication].